All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
Bookmark this article
In May 2016, Glass et al. published in the Journal of Clinical Oncology the results of a phase I/II study into the efficacy of methotrexate, temozolomide (TMZ) with rituximab, proceeded by hyperfractionated Whole-Brain Radiotherapy (hWBRT) in patients with Primary CNS Lymphoma (PCNSL), followed by maintenance treatment with TMZ. The reported 2-year OS and PFS were 80.8% and 63.6%, respectively.
In a more recent correspondence, also in the Journal of Clinical Oncology, Marc C. Chamberlain, of the University of Washington and Fred Hutchinson Cancer Research Center, Seattle, responded to these results explaining potential issues with the study. The key points of concern were:
In conclusion, both the authors of the original study and Marc Chamberlain state that randomized trials are needed to elucidate the value of these protocol modifications for treatment of PCNSL. Marc Chamberlain also suggested that deciding upon which regimen a patient should follow is based on “interpretation of a confusing literature”, and the physician’s familiarity with and subjective opinions of therapies, amplifying the need for more randomized, multi-arm studies.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox